

Credit Suisse Global Healthcare Exposure 6.5% 2-Factor Risk Control (ER) Monthly Report - February 2021

Bloomberg Index Ticker

CSEAGH2F Index

Return Type

Excess Return

Currency

USD

Live Date

02 December 2020



Investment Strategy

The Credit Suisse Global Healthcare Exposure 6.5% (ER) Index is an investible long-only index which allocates between an equity index providing exposure to companies deriving revenues from healthcare even though their primary focus might be different (Solactive Global Healthcare Exposure USD Index NTR – SOLGHUNR Index) and a long only fixed income strategy investing across nine treasury futures globally (Credit Suisse G9 Bond Dynamic Carry Long Only Index – CIRBBG9L Index).

The Index targets a volatility of 6.5% and aims to benefit from the realised de-correlation between the Equity and the Fixed Income Component to achieve simultaneous exposure to both components subject to risk limits. This enhanced volatility target strategy allows to optimize the overall index exposure by allocating into a defensive asset during periods of equity market stress.

Historical Performance



Monthly returns - Last 5 Years

	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2016	0.2%	0.6%	1.8%	0.1%	0.7%	1.4%	2.0%	-0.9%	-0.1%	-3.5%	-2.4%	1.6%	1.4%
2017	-1.4%	3.8%	0.7%	1.4%	1.8%	0.0%	-0.8%	0.9%	0.7%	0.2%	1.4%	0.3%	9.3%
2018	2.0%	-4.7%	0.6%	-0.5%	-1.5%	-0.7%	3.0%	-0.1%	0.5%	-3.2%	2.0%	-1.4%	-4.1%
2019	2.6%	1.0%	2.2%	-0.7%	-0.5%	4.4%	1.0%	0.9%	0.7%	1.3%	1.5%	0.9%	16.4%
2020	-0.5%	-5.6%	-4.5%	1.0%	0.4%	-0.2%	-0.3%	1.0%	0.7%	-0.8%	1.5%	0.7%	-6.6%
2021	-0.9%	-3.0%											-3.8%

Source: Credit Suisse

Figures refer to past performance. All figures based on data from 17 May 2006 to 26 February 2021. Credit Suisse Global Healthcare Exposure 6.5% 2-Factor Risk Control (ER) is live since 02 December 2020. Any performance prior to that date is simulated. Neither simulated nor historical performance is an indicator of future performance. Credit Suisse Global Healthcare Exposure 6.5% 2-Factor Risk Control (ER) returns are net of 1.50% p.a. index fee and applicable access and transaction costs. Please see the important information at the end of this material.


These materials do not constitute an offer or a solicitation of an offer to buy or sell investment products or securities, nor do they constitute a prospectus for any securities, nor do they otherwise constitute an agreement to provide investment services. These materials are provided for information purposes only and do not contain all of the information that is material to an investor. For more information on the Index (including Index Rules and Risk Disclosures), please contact your Credit Suisse representative.

Credit Suisse Global Healthcare Exposure 6.5% 2-Factor Risk Control (ER) Monthly Report - February 2021


Performance Statistics

	1 Month	3 Months	6 Months	Year To Date	1 Year	3 Years	5 Years	Since Start
Return	-3.0%	-3.1%	-1.7%	-3.8%	-7.1%	2.6%	10.4%	58.4%
Volatility (p.a)	6.5%	5.0%	4.7%	5.8%	6.5%	6.0%	6.0%	5.9%
Sharpe Ratio	-5.0	-2.5	-0.7	-3.7	-1.1	0.1	0.3	0.5
Max Drawdown	-3.6%	-4.1%	-4.1%	-4.1%	-9.1%	-13.0%	-13.0%	-15.5%
Best Month	N/A	0.7%	1.5%	-0.9%	1.5%	4.4%	4.4%	4.4%
Worst Month	N/A	-3.0%	-3.0%	-3.0%	-4.5%	-5.6%	-5.6%	-5.6%
Positive Months	N/A	33.3%	50.0%	0.0%	46.2%	54.1%	62.3%	59.6%

Average Weights Through Month



Performance Contribution Through Month



Monthly Component Breakdown

Index Component	Ticker	Monthly Performance	Performance Contribution	Current Weight	Average Weight	Previous Weight	Weight Change
Credit Suisse G9 Bond Dynamic Carry Long Only	CIRBBG9L	-2.8%	-1.75%	62.2%	61.9%	62.1%	0.1%
Solactive Global Healthcare Exposure USD Index Net Excess Return	SOLGHUNR Excess Return	-2.9%	-1.10%	38.0%	38.3%	37.9%	0.0%

Source: Credit Suisse

Figures refer to past performance. All figures based on data from 17 May 2006 to 26 February 2021. Credit Suisse Global Healthcare Exposure 6.5% 2-Factor Risk Control (ER) is live since 02 December 2020. Any performance prior to that date is simulated. Neither simulated nor historical performance is an indicator of future performance. Credit Suisse Global Healthcare Exposure 6.5% 2-Factor Risk Control (ER) returns are net of 1.50% p.a. index fee and applicable access and transaction costs. Please see the important information at the end of this material.

These materials do not constitute an offer or a solicitation of an offer to buy or sell investment products or securities, nor do they constitute a prospectus for any securities, nor do they otherwise constitute an agreement to provide investment services. These materials are provided for information purposes only and do not contain all of the information that is material to an investor. For more information on the Index (including Index Rules and Risk Disclosures), please contact your Credit Suisse representative.

Credit Suisse Global Healthcare Exposure 6.5% 2-Factor Risk Control (ER)

Monthly Report - February 2021

Disclaimer

These materials do not constitute an offer or a solicitation of an offer to buy or sell investment products or securities, nor do they constitute a prospectus for any securities, nor do they otherwise constitute an agreement to provide investment services. These materials are provided for information purposes only and do not contain all of the information that is material to an investor. By reading these materials, you agree as follows:

These materials and any associated oral presentation or discussion (together the “materials”) are strictly confidential and have been provided to you by Credit Suisse International and/or its affiliates (together, “Credit Suisse”, “we” or “us”) and may not be used or relied upon unless expressly agreed in writing with us. These materials and the information contained herein are intended solely for your information and may not be disclosed or distributed to any other person, or otherwise replicated in any form without the prior written consent of Credit Suisse.

These materials are not for distribution to Retail Clients, as defined by the FCA Rules. Any investment or services to which these materials may relate will not be made available to Retail Clients.

CREDIT SUISSE IS ACTING SOLELY AS AN ARM'S LENGTH CONTRACTUAL COUNTERPARTY AND NOT AS A FINANCIAL ADVISER (OR IN ANY OTHER ADVISORY CAPACITY INCLUDING TAX, LEGAL, ACCOUNTING OR OTHERWISE) OR IN A FIDUCIARY CAPACITY. ANY INFORMATION PROVIDED DOES NOT CONSTITUTE ADVICE OR A RECOMMENDATION TO ENTER INTO OR CONCLUDE ANY TRANSACTION. BEFORE ENTERING INTO ANY TRANSACTION WITH US, YOU SHOULD ENSURE THAT YOU FULLY UNDERSTAND THE POTENTIAL RISKS AND REWARDS AND INDEPENDENTLY DETERMINE THAT IT IS APPROPRIATE FOR YOU GIVEN YOUR OBJECTIVES, EXPERIENCE, FINANCIAL AND OPERATIONAL RESOURCES, AND OTHER RELEVANT CIRCUMSTANCES. YOU SHOULD CONSULT WITH SUCH ADVISERS (INCLUDING, WITHOUT LIMITATION, TAX ADVISERS, LEGAL ADVISERS AND ACCOUNTANTS) AS YOU DEEM NECESSARY.

This material has been prepared by us based on assumptions and parameters determined by us in good faith. The assumptions and parameters used are not the only ones that might reasonably have been selected and therefore no guarantee is given as to the accuracy, completeness or reasonableness of any such quotations, disclosure or analyses. A variety of other or additional assumptions or parameters, or other market factors and other considerations, could result in different contemporaneous good faith analyses or assessment of the transaction described above.

Past performance should not be taken as an indication or guarantee of future performance, and no representation or warranty, express or implied, is made regarding future performance. We assume no responsibility for independent verification of such information and have relied on such information being complete and accurate in all material respects. Any commentary in these materials constitutes our preliminary judgment at, and is based solely on the information received by us before, the date hereof and is subject to change without notice.

We make no representation as to the completeness or accuracy of the information. We do not accept any liability for any direct, indirect or consequential loss or damage arising from reliance on this information.

The price and value of investments mentioned and any income that might accrue may fluctuate and may fall or rise. If an investment is denominated in a currency other than your base currency, changes in the rate of exchange may have an adverse effect on value, price or income.

All projections, valuations and analyses are provided to assist you in the evaluation of the matters described herein and (i) may be based on subjective assessments and assumptions, (ii) may use one among alternative methodologies that produce different results and (iii) to the extent they are based on historical information, should not be relied upon as an accurate prediction of future performance. Certain analysis is presented herein and is intended solely for purposes of indicating a range of outcomes that may result from changes in market parameters. It is not intended to suggest any outcome is more likely than another, and it does not include all possible outcomes or the range of possible outcomes, one of which may be that the investment value declines to zero. All projections and forecasts in these materials are therefore illustrative only.

Back-tested, hypothetical or simulated performance results have inherent limitations. Simulated results are achieved by the retroactive application of a back-tested model itself designed with the benefit of hindsight. The back-testing of performance differs from the actual account performance because the investment strategy may be adjusted at any time, for any reason and can continue to be changed until desired or better performance results are achieved. Alternative modeling techniques or assumptions might produce significantly different results and prove to be more appropriate. Past hypothetical back-test results are neither an indicator nor a guarantee of future returns. Actual results will vary from the analysis.

To the extent that the products are structured securities or other forms of structured products, such instruments are complex instruments, typically involving a high degree of risk and are intended for sale only to sophisticated investors who are capable of understanding and assuming the risks involved. The market value of any structured security or structured product may be affected by changes in economic, financial and political factors (including, but not limited to, spot and forward interest and exchange rates), time to maturity, market conditions and volatility and the credit quality of any issuer or reference issuer. Any investor interested in purchasing a structured product should conduct its own investigation and analysis of the product and consult with its own professional advisers as to the risks involved in making such a purchase.

These materials were designed for use by specific persons familiar with the business and the affairs of your company and we assume no obligation to update or otherwise revise these materials.

Credit Suisse or its employees may have a position or holding, or other material interest, or effect transactions in, any securities mentioned or options thereon, or other investments related thereto. We may provide (or have already provided) significant advice or investment services in relation to the investment concerned or a related investment to any company or issuer mentioned. Some investments referred to in this information will be offered by a single entity and, in the case of some investments, solely by us, or one of our affiliates. We have no obligation to use any information obtained from another source for the purposes of any the activities contemplated herein or to furnish such information to you or your affiliates.

Credit Suisse has adopted policies and guidelines designed to preserve the independence of its research analysts. Credit Suisse's policies prohibit employees from directly or indirectly offering a favorable research rating or specific price target, or offering to change a research rating or price target, as consideration for or an inducement to obtain business or other compensation. Credit Suisse's policies prohibit research analysts from being compensated for their involvement in investment banking transactions. This document does not constitute investment research or a research recommendation.

Credit Suisse International (“CSI”) which is authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority.

Additional information is available from us upon request.

Copyright © 2021 Credit Suisse Group AG and/or its affiliates. All rights reserved.